On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.

On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.

Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.

Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.

Argo Biopharma unveiled exclusive RNAi therapy licensing deals with Novartis Pharma.

Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.

Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.

On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.

On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.

GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.

Kymera Therapeutics began their Phase 2 ADVANTA study for KT-474 in AD on Dec 7, 2023, prompting a $15M milestone payment from Sanofi.